LINCOLN, Neb. -- (BUSINESS WIRE) -- Celerion is pleased to announce the appointment of Robert Lester MD FACC, as Chief Cardiologist, Global Medical Director of Cardiac Safety Services. Dr. Lester will develop and lead Celerion’s strategic vision in Cardiac Safety Services. He will be based in our state-of-the-art facility in Phoenix, Arizona.
Dr. Lester comes to Celerion with over 25 years’ experience in clinical medicine and academia, as well as over 13 years’ experience as a Director and Senior Cardiologist at several leading Contract Research Organizations (CROs) and ECG Core labs. Dr. Lester will utilize his extensive experience and expertise in the area of cardiac safety, to provide advice and lead client programs. He will also be a driving force for Celerion’s innovative Highly Automated ECG Core Lab that enables clients to expedite ECG review, thereby significantly reducing the time and cost for cardiac safety studies over traditional approaches.
“The appointment of Robert continues to reinforce Celerion’s leadership role in the area of cardiac safety studies,” said Phil Bach, Vice President of Global Clinical Research at Celerion. “His comprehensive expertise and knowledge in the area of cardiac safety will be invaluable for Celerion and for our clients. Robert will also lead the efforts to ensure we meet the needs of our clients, as the regulatory landscape changes.”
Dr. Lester earned his BA with highest honors in Sociology at Princeton University and a doctorate in Medicine at Duke University Medical School. He continued his training at Duke University Medical Center in Internal Medicine and Cardiology. Thereafter he was recruited by the National Institutes of Health as an Expert Consultant in Cardiac Critical Care medicine where he became acting Chairman of that Department. This was followed by professorships at the University of Pennsylvania and University of Minnesota before entering the CRO industry in 2001. Dr. Lester is the author of numerous publications, and has been an invited speaker at leading conferences and key organizations.
Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.
With over 40 years of experience and 750 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical Proof-of-Concept, Cardiac Safety Services (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. For more information please visit www.celerion.com.